Zipes              D.P., Camm A.J., Borggrefe M., Buxton A.E., Chaitman B., Fromer M. et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society // Europace. - 2006. - Vol. 8. - P. 746-837.
Niimura              H., Bachinski L.L., Sangwatanaroj S. et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy // N. Engl. J. Med. - 1998. - Vol. 338. - P. 1248-1257.
Fatkin              D., Graham R.M. Molecular mechanisms of inherited cardiomyopathies // Physiol. Rev. - 2002. -
- P. 945-980.
Watkins              H., McKenna W.J., Thierfelder L. et al. Mutations in the genes for cardiac troponin T and alpha- tropomyosin in hypertrophic cardiomyopathy // N. Engl. J. Med. - 1995. - Vol. 332. - P. 1058-1064.
Keren              A., Syrris P., McKenna W.J. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression // Nat. Clin. Pract. Cardiovasc. Med. - 2008. - Vol. 5. - P. 747.
Marian              A.J. Genetic determinants of cardiac hypertrophy // Curr. Opin. Cardiol. - 2008. - Vol. 23. - P. 199-205.
Binder              J., Ommen S.R., Gersh B.J., et al. Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations // Mayo Clin. Proc. - 2006. - Vol. 81. - P. 459-467.
8.Solomon S.D., Wolff S., Watkins H., et al. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene // J. Am. Coll. Cardiol. - 1993. - Vol. 22. - P. 498-505.
Richard              P., Charron P., Carrier L., et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy // Circulation. - 2003. - Vol.
- P. 2227-2232.
van              der Merwe L., Cloete R., Revera M., et al. Genetic variation in angiotensin-converting enzyme 2 gene is associated with extent of left ventricular hypertrophy in hypertrophic cardiomyopathy // Hum. Genet. - 2008. - Vol. 124. - P. 57-61.
.Daw E.W., Chen S.N., Czernuszewicz G., et al. Genome-wide mapping of modifier chromosomal loci for human hypertrophic cardiomyopathy // Hum. Mol. Genet. - 2007. - Vol. 16. - P. 2463-2471.
Wang              P., Zou Y., Fu C., et al. MYBPC3 polymorphism is a modifier for expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy // Biochem. Biophys. Res. Commun. - 2005. - Vol. 329. - P. 796-799.
Karkkainen              S., Peuhkurinen K. Genetics of dilated cardiomyopathy // Ann. Med. - 2007. - Vol. 39. - P. 91-107.
Marian              AJ, Yu QT, Workman R, et al. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death // Lancet. - 1993. - Vol. 342. - P. 1085-1086.
Brugada              R., Kelsey W., Lechin M., et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy // J. Investig. Med. - 1997. - Vol.
- P. 542-551.
Patel              R., Lim D.S., Reddy D., et al. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy // J. Mol. Cell Cardiol. - 2000. - Vol. 32. - P. 2369-2377.
17.Olson T.M., Michels V.V., Thibodeau S.N., et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure // Science. - 1998. - Vol. 280. - P. 750-752.
18.Schmitt J.P., Debold E.P., Ahmad F, et al. Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function // Proc. Natl. Acad. Sci. USA.
- Vol. - 103. - P. 14525-14530.
Knoll              R., Hoshijima M., Hoffman H.M., et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy // Cell. - 2002. - Vol. 111. - P. 943-955.
Fuchs              E., Cleveland D.W. A structural scaffolding of intermediate filaments in health and disease // Science. - 1998. - Vol. 279. - P. 514-519.
21 .Cox G.F., Kunkel L.M. Dystrophies and heart disease // Curr. Opin. Cardiol. - 1997. - Vol. 12. - P. 329343.
22.Suomalainen A., Paetau A., Leinonen H., et al. Inherited idiopathic dilated cardiomyopathy with multiple deletions of mitochondrial DNA // Lancet. - 1992. - Vol. 340. - P. 1319-1320.
23.Shin W.S., Tanaka M., Suzuki J., et al. A novel homoplasmic mutation in mtDNA with a single evolutionary origin as a risk factor for cardiomyopathy // Am. J. Hum. Genet. - 2000. - Vol. 67. - P. 16171620.
Taniike              M., Fukushima H., Yanagihara I., et al. Mitochondrial tRNA(Ile) mutation in fatal cardiomyopathy // Biochem. Biophys. Res. Commun. - 1992. - Vol. 186. - P. 47-53.
D’Adamo              P., Fassone L., Gedeon A., et al. The X-linked gene G4.5 is responsible for different infantile dilated cardiomyopathies // Am. J. Hum. Genet. - 1997. - Vol. 61. - P. 862-867.
26.Ichida F., Tsubata S,. Bowles K.R., et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome // Circulation. - 2001. - Vol. 103. - P. 1256-1263.
Vatta              M., Mohapatra B., Jimenez S., et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction // J. Am. Coll Cardiol. - 2003. - Vol. 42. - P. 20142027.
McKenna              W.J., Thiene G., Nava A., et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology // Br. Heart J. - 1994. - Vol. 71. - P. 215-218.
Thiene              G., Corrado D., Basso C. Arrhythmogenic right ventricular cardiomyopathy/dysplasia // Orphanet. J. Rare. Dis. - 2007. - Vol. 2. - P. 45.
Wichter              T., Paul M., Wollmann C., et al. Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients // Circulation. - 2004. - Vol. 109. - P. 1503-1508.
Turrini              P., Corrado D., Basso C. Dispersion of ventricular depolarization-repolarization: a noninvasive marker for risk stratification in arrhythmogenic right ventricular cardiomyopathy // Circulation. - 2001. - Vol. 103. - P. 3075-3080.
32.Sen-Chowdhry S., Syrris P., McKenna W.J. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy // J. Am. Coll. Cardiol. - 2007. - Vol. 50. - P. 1813-1821.
Gray              J.R., Davies S.J. Marfan syndrome // J. Med. Genet - 1996 May. - Vol. 33. - P. 403-408.
De              Paepe A., Devereux R.B., Dietz H.C. Revised diagnostic criteria for the Marfan syndrome // Am J Med. Genet. - 1996. - Vol. 62. - P. 417-426.
Dietz              H.C., Cutting G.R., Pyeritz R.E., et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene // Nature. - 1991. - Vol. 352. - P. 337-339.
Collod              G., Babron M.C., Jondeau G. et al. A second locus for Marfan syndrome maps to chromosome 3p24.2-p25 // Nat .Genet. - 1994. - Vol. 8. - P. 264-268.
Priori              S.G., Napolitano C., Schwartz P.J. Genetics of cardiac arrhythmias. In Zipes D.P., Libby P., Bonow RO, et al. (eds). Braunwald’s Heart Disease, 7th edn. - 2004. - Philadelphia, PA: Elsevier Saunders. -P. 689-695.
Napolitano              C., Priori S.G., Schwartz P.J. et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice // JAMA. - 2005. - Vol. 294. -
P. 2975-2980.
39.Schwartz P.J., Priori S.G. Long QT syndrome - phenotype genotype considerations. In Zipes D.P., Jalife J (eds.) Cardiac Electrophysiology, 4th edn. - 2004. Philadelphia, PA: Elsevier. - P. 651-667.
Ueda              K., Valdivia C., Medeiros-Domingo A, et al. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex // Proc. Natl. Acad. Sci. USA.
2008. - Vol. 105. - P. 9355-9360.
Chen              L., Marquardt M.L., Tester D.J. et al. Mutation of an A-kinase-anchoring protein causes long-QT syndrome // Proc. Natl. Acad. Sci. USA. - 2007. - Vol. 104. - P. 20990-20995.
Vatta              M., Ackerman M.J., Ye B. et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome // Circulation. - 2006. - Vol. 114. - P. 2104-2112.
Mohler              P.J., Le Scouarnec S., Denjoy I. et al. Defining the cellular phenotype of ankyrin-B syndrome variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes // Circulation. - 2007. - Vol. 115. - P. 432-441.
44.Schwartz P.J., Priori S.G. Newer approaches to management of the long QT syndrome. In Braunwald E (ed.) Harrison’s Advances in Cardiology. - 2004. - New York: McGraw Hill. - P. 339-398.
Priori              S.G., Napolitano C., Schwartz P.J. et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers // JAMA. - 2004. - Vol. 292. - P. 1341-13414.
Vincent              G.M. High efficacy of beta-blockers in long QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment failures // Circulation in press.
Priori              S.G., Rivolta I., Napolitano C. Genetics of long QT, Brugada and other Channellopathies. In Zipes DP, Jalife J (eds.) Cardiac Electrophysiology, 4th edn. - 2004. - Philadelphia, PA: Elsevier. - P. 462470.
Gouas              L., Bellocq C., Berthet M. et al. New KCNQ1 mutations leading to haploinsufficiency in a general population. - Defective trafficking of a KvLQT1 mutant // Cardiovasc. Res. - 2004. - Vol. 63. - P. 60-68.
Zhou              Z., Gong Q., Epstein M.L. et al. HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects // J. Biol. Chem. - 1998. - Vol. 273 - P. 21061-21066.
Compton              S.J., Lux R.L., Ramsey M.R., et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium // Circulation. - 1996. - Vol. 94. - P. 10181022.
51 .Etheridge S.P., Compton S.J., Tristani-Firouzi M. et al. A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations // J. Am. Coll. Cardiol.
2003. - Vol. 42. - P. 1777-1782.
Zhou              Z., Gong Q., January C.T. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects // J. Biol. Chem. - 1999. - Vol. 274. - P. 31123-31126.
Rajamani              S., Anderson C.L., Anson B.D. et al. Pharmacological rescue of human K(+) channel long- QT2 mutations: human ether-a-go-go-related gene rescue without block // Circulation. - 2002. - Vol. 105. - P. 2830-2835.
Ruan              Y., Liu N., Bloise R. et al. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients // Circulation. - 2007. - Vol. 116. - P. 1137-1144.
Rossenbacker              T, Priori SG. The Brugada syndrome // Curr Opin Cardiol. - 2007. - Vol. 22. - P. 163170.
Thomas              K., Grant A.O. Ethnicity and arrhythmia susceptibility // J. Cardiovasc. Electrophysiol. - 2008. - Vol. 19. - P. 427-429.
Bezzina              C.R., Shimizu W., Yang P. et al. Common sodium channel promoter haplotype in asian subjects underlies variability in cardiac conduction // Circulation. - 2006. - Vol. 113. - P. 338-344.
Antzelevitch              C., Brugada P., Borggrefe M. et al. Brugada Syndrome. Report of the Second Consensus Conference. Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association // Circulation. - 2005. - Vol. 111. - P. 659-670.
Priori              S.G., Napolitano C., Gasparini M. et al. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families // Circulation. - 2000. - Vol. 102. - P. 2509-2515.
Miyamoto              K., Yokokawa M., Tanaka K. et al. Diagnostic and prognostic value of a type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome // Am. J. Cardiol. - 2007. - Vol. 99. - P. 53-57.
61 .Probst V., Denjoy I., Meregalli P.G. et al. Clinical aspects and prognosis of Brugada syndrome in children // Circulation. - 2007. - Vol. 115 - P. 2042-2048.
Brugada              J., Brugada R., Antzelevitch C. et al. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads
V1              to V3 // Circulation. - 2002. - Vol. 105. - P. 73-78.
Miyazaki              T., Mitamura H., Miyoshi S. et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome // J. Am. Coll. Cardiol. - 1996. - Vol. 27. - P. 10611070.
Eckardt              L., Probst V., Smits J.P.P. et al. Long-term prognosis of individuals with right precordial ST- segment-elevation Brugada syndrome // Circulation. - 2005. - Vol. 111. - P. 257-263.
Priori              SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome. insights for risk stratification and management // Circulation. - 2002 Feb 25. - Vol. 105. - P. 1342-1347.
Gehi              A.K., Duong T.D., Metz L.D. et al. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis // J. Cardiovasc. Electrophysiol. - 2006. - Vol. 17. - P. 577-583.
Probst              V., Allouis M., Sacher F. et al. Progressive cardiac conduction defect is the prevailing phenotype in carriers of a Brugada syndrome SCN5A mutation // J. Cardiovasc. Electrophysiol. - 2006. - Vol. 17. - P. 270-275.
Bai              R., Napolitano C., Bloise R. et al. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing // Circ. Arrhythm. Electrophysiol. - 2009. - Vol. 2. - P. 6-15.
London              B, Shamarendra S, Michalec M, et al. A mutation in the glycerol-3-phosphate dehydrogenase 1-like gene (GPD1L) causes Brugada syndrome // Heart Rhythm. - 2006. - S32(abstract).
Antzelevitch              C., Pollevick G.D., Cordeiro J.M. et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death // Circulation. - 2007. - Vol. 115. - P. 442-449.
71.Saura D., Garcia-Alberola A., Carrillo P. et al. Brugada-like electro-cardiographic pattern induced by fever // Pacing. Clin. Electro-physiol. - 2002. - Vol. 25. - P. 856-859.
72.Schott J.J., Alshinawi C., Kyndt F. et al. Cardiac conduction defects associate with mutations in SCN5A // Nat. Genet. - 1999. - Vol. 23. - P. 20-21.
73.Benson D.W., Wang D.W., Dyment M. et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A) // J. Clin. Invest. - 2003. - Vol. 112. - P. 10191028.
74.Schulze-Bahr E., Neu A., Friederich P. et al. Pacemaker channel dysfunction in a patient with sinus node disease // J. Clin. Invest. - 2003. - Vol. 111. - P. 1537-1545.
Andalib              A., Brugada R., Nattel S. Atrial fibrillation: evidence for genetically determined disease // Curr. Opin. Cardiol. - 2008. - Vol. 23. - P. 176-183.
Chen              Y.H., Xu S.J., Bendahhou S. et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation // Science. - 2003. - Vol. 299. -
P. 251-254.
Gussak              I., Brugada P., Brugada J. et al. Idiopathic short QT interval: a new clinical syndrome? // Cardiology. - 2000. - Vol. 94. - P. 99-102.
78.Schimpf R., Wolpert C., Gaita F. Short QT syndrome // Cardiovasc. Res. - 2005. - Vol. 67. - P. 357366.
Priori              S.G., Pandit S.V., Rivolta I. et al. A novel form of short QT syndrome (SQT3)              is              caused              by a
mutation in the KCNJ2 gene // Circ Res. - 2005. - Vol. 96. - P. 800-807.
Brugada              R., Hong K., Dumaine R. et al. Sudden death associated with short-QT syndrome linked to mutations in HERG // Circulation. - 2004. - Vol. 109. - P. 30-35.
81 .Bellocq C., van Ginneken A.C., Bezzina C.R. et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome // Circulation. - 2004. - Vol. 109. - P. 2394-2397.
Reid              DS, Tynan M., Braidwood L. et al. Bidirectional tachycardia in a child. A study              using              His              bundle
electrography // Br. Heart J. - 1975. - Vol. 37. - P. 339-344.
Coumel              P., Fidelle J., Lucet V. et al. Catecholaminergic-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases // Br. Heart J. - 1978. - Vol. 40. - P. 28-37.
Rossenbacker              T., Bloise R., De Giuli L. et al. Catecholaminergic polymorphic ventricular tachycardia: genetics, natural history and response to therapy // Circulation. - 2007. - Vol. 116 (Suppl.II). - P. 179.
Priori              S.G., Napolitano C., Tiso N. et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia // Circulation. - 2001. - Vol. 103. - P. 196200.
George              C.H., Jundi H., Thomas N.L. et al. Ryanodine receptors and ventricular arrhythmias: emerging trends in mutations, mechanisms and therapies // J. Mol. Cell. Cardiol. - 2007. - Vol. 42. - P. 34-50.
Lahat              H., Pras E., Eldar M. RYR2 and CASQ2 mutations in patients suffering from catecholaminergic polymorphic ventricular tachycardia // Circulation. - 2003. - Vol. 107. - e29.
Rizzi              N., Liu N., Napolitano C. et al. Autosomal recessive catecholaminergic Polymorphic verntricular tachycardia: pathophysiological insights from a knock-in mouse model. (Submitted).
Liu              N., Ruan Y., Priori S.G. Catecholaminergic polymorphic ventricular tachycardia // Prog. Cardiovasc. Dis. - 2008. - Vol. 51. - P. 23-30.
Liu              N., Priori S.G. Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin // Cardiovasc. Res. - 2008. - Vol. 15. - Vol. 77. - P. 293301.
Cerrone              M., Noujaim S.F., Tolkacheva E.G. et al. Arrhythmogenic Mechanisms in a Mouse model of catecholaminergic polymorphic ventricular tachycardia // Circ. Res. - 2007. - Vol. 11. - P. 1039-1048.
Bhuiyan              Z.A., Hamdan M.A., Shamsi E.T. et al. A novel early onset lethal form of catecholaminergic polymerphic ventricular tachycardia maps to chromosome 7p14-p22 // J. Cardiovasc. Electrophysiol. -
- Vol. 18. - P. 1060-1066.
Mohler              P.J., Splawski I., Napolitano C. et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function // Proc. Natl. Acad. Sci. USA. - 2004. - Vol. 101. - P. 9137-9142.
Plaster              N.M., Tawil R., Tristani-Firouzi M. et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome // Cell. - 2001. - Vol. 105. - P. 511-519.
Ruan              Y., Theiade J., Memmi M. et al. KCNJ2 mutations in patients referred for catecholaminergic polymorphic ventricular tachycardia gene screening // Circulation in press.
Viswanathan              PC, Benson DW, Balser JR. A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation // J. Clin. Invest. - 2003. - Vol. 111. - P. 341-346.
Bezzina              C.R., Verkerk A.O., Busjahn A. et al. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization // Cardiovasc. Res. - 2003. - Vol. 59. - P. 27-36.
98.Splawski I., Timothy K.W., Tateyama M. et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia // Science. - 2002. - Vol. 297. - P. 1333-1336.
Roden              D.M., Viswanathan P.C. Genetics of acquired long QT syndrome // J. Clin. Invest. - 2005. - Vol.
- P. 2025-2032.
Arking              D.E., Pfeufer A., Post W. et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization // Nat. Genet. - 2006. - Vol. 38. - P. 644-651.
Varret              M., Abifadel M., Rabes J.P. et al. Genetic heterogeneity of autosomal dominant hypercholesterolemia // Clin. Genet. - 2008. - Vol. 73. - P. 1-13.
Marks              D., Thorogood M., Neil H.A. et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia // Atherosclerosis. - 2003. - Vol. 168. - P. 1-14.
Neil              A., Cooper J., Betteridge J. et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study // Eur. Heart. J. - 2008. - Vol. 29. - P. 2625-2633.
NICE              Familial Hypercholesterolaemiai. Available at: http://www.nice.org.uk/nicemedia/pdf/CG071. NICE.
Wierzbicki              A.S., Humphries S.E., Minhas, R. Familial hypercholesterolaemia: summary of NICE guidance // BMJ. - 2008. - Vol. 337. - a1095.
106.Starr B., Hadfield S.G., Hutton B.A. et al. Development of sensitive and specific age- and gender- specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing // Clin. Chem. Lab. Med. - 2008. - Vol. 46. - P. 791-803.
Civeira              F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia // Atherosclerosis. - 2004. - Vol. 173. - P. 55-68.
Umans-Eckenhausen              M.A., Defesche J.C., Sijbrands E.J. et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands // Lancet. - 2001. - Vol. 357. - P. 165-168.
Alonso              R., Mata N., Castillo S. et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors // Atherosclerosis. -
- Vol. 200. - P. 315-321.
Leren              T.P., Finborud T.H., Manshaus T.E. et al. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening // Community Genet. - 2008. - Vol. 11. - P. 26-35.
Leigh,              S.E., Foster A.H., Whittall R.A. et al. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database // Ann. Hum. Genet. - 2008. - Vol. 72. - P. 485-498.
Leren              T.P. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia // Clin. Genet. - 2004. - Vol. 65. - P. 419-422.
Timms              K.M., Wagner S., Samuels M.E., et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree // Hum. Genet. - 2004. - Vol. 114. - P. 349-353.
114.Sun X.M., Eden E.R., Tosi I. et al. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia // Hum. Mol. Genet. - 2005. - Vol. 14. - P. 1161-1169.
Humphries              S.E., Whittall R.A., Hubbart C.S. et al. Genetic causes of familial hypercholesterolaemia in UK patients: relation to plasma lipid levels and coronary heart disease risk // J. Med. Genet. - 2006. - Vol. 43. - P. 943-949.
Humphries              S.E., Norbury G., Leigh S. et al. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? // Curr. Opin. Lipidol. - 2008. - Vol. 19. - P. 362-368.
Taylor              A., Tabrah S., Wang D. et al. Multiplex ARMS analysis to detect 13 common mutations in familial hypercholesterolaemia // Clin. Genet. - 2007. - Vol. 71. - P. 561-568.
Wright              W., Heggarty S., Young I.S. et al. Multiplex MassARRAY spectrometry (iPLEX) produces a fast and economical test for 56 familial hypercholesterolaemia-causing mutations // Clin. Genet. - 2008. - Vol. 74. - P. 463-468.
Lombardi              M.P., Redeker E.J., Defesche J.C. et al. Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands // Clin. Genet. - 2000. - Vol. 57. - P. 116-124.
Holla              0.L., Teie C., Berge K.E. et al. Identification of deletions and duplications in the low density lipoprotein receptor gene by MLPA // Clin. Chim. Acta. - 2005. - Vol. 356. - P. 164-171.
121.Stephens JW, Humphries SE. The molecular genetics of cardiovascular disease: clinical implications // J. Intern. Med. - 2003. - Vol. 253. - P. 120-127.
Beekman              M., Heijmans B.T., Martin N.G. et al. Heritabilities of apolipoprotein and lipid levels in three countries // Twin. Res. - 2002. - Vol. 5. - P. 87-97.
Worns              M.A., Victor A., Galle P.R. et al. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels - a study in twins // Genes. Immun. - 2006. - Vol. 7. - P. 600-605.
Ariens              R.A., de Lange M, Sneider H, et al. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state // Lancet. - 2002. - Vol. 359. - P. 667-671.
Austin M.A., Sandholzer C., Selby J.V. et al. Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes // Am. J. Hum. Genet. - 1992. - Vol. 51. - P. 829-840.
Boerwinkle              E., Leffert C.C., Lin J. et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations // J. Clin. Invest. - 1992. - Vol. 90. - P. 52-60.
Danesh              J., Collins R., Peto R.. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies // Circulation. - 2000. - Vol. 102. - P. 1082-1085.
128.Shiffman D., O’Meara E.S., Bare L.A. et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study // Arterioscler. Thromb. Vasc. Biol. - 2008. - Vol. 28. - P. 173-179.
Colhoun              H.M., McKeigue P.M., Davey Smith G. Problems of reporting genetic associations with complex outcomes // Lancet. - 2003. - Vol. 361. - P. 865-872.
Bennet              A.M., Di Angelantonio E., Ye Z. et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk // JAMA. - 2007. - Vol. 298. - P. 1300-1311.
Humphries              S.E., Talmud P.J., Hawe E. et al. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study // Lancet. - 2001. - Vol. 358. - P. 115-119.
Humphries              S.E., Hawe E., Dhamrait S. et al. In search of genetic precision // Lancet. - 2003. - Vol. 361. - P. 1908-9. - author reply 1909-1910.
Talmud              P.J., Stephens J.W., Hawe E. et al. The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: potential relationship between reduced antioxidant status and ApoE4 // Ann. Hum. Genet. - 2005. - Vol. 69. - P. 613-622.
Talmud              P.J., Lewis S.J., Hawe E. et al. No APOEepsilon4 effect on coronary heart disease risk in a cohort with low smoking prevalence: the Whitehall II study // Atherosclerosis. - 2004. - Vol. 177. - P. 105
112.
Morgan              T.M., Coffey C.C.S, Krumholz HM. Overestimation of genetic risks owing to small sample sizes in cardiovascular studies // Clin. Genet. - 2003. - Vol. 64. - P. 7-17.
Drenos              F., Whittaker J.C., Humphries S.E. The use of meta-analysis risk estimates for candidate genes in combination to predict coronary heart disease risk // Ann. Hum. Genet. - 2007. - Vol. 71. - P. 611-619.
Ntzani              E.E., Rizos E.C., Ioannidis J.P. Genetic effects versus bias for candidate polymorphisms in myocardial infarction: case study and overview of large-scale evidence // Am. J. Epidemiol. - 2007. - Vol.
- P. 973-984.
Abilleira              S., Bevan S., Markus H.S. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis // J. Med. Genet. - 2006. - Vol. 43. - P. 897-901.
Clarke              R., Xu P., Bennett D. et al. Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study // PLoS Genet. - 2006. - 2: e107.
Hu              Y., Liu W., Huang R. et al. A systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases // J. Lipid. Res. - 2006. - Vol. 47 - P. 1908-1914.
Xu              M.Q., Ye Z., Hu F.B. et al. Quantitative assessment of the effect of angiotensinogen gene polymorphisms on the risk of coronary heart disease // Circulation. - 2007. - Vol. 116. - P. 1356-1366.
Ye              Z., Liu E.H., Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls // Lancet. - 2006. - Vol. 367. - P. 651-658.
143.Sie M.P., Sayed-Tabatabaei F.A., Oei H.H. et al. Interleukin 6-174g/c promoter polymorphism and risk of coronary heart disease: results from the Rotterdam study and a meta-analysis // Arterioscler. Thromb. Vasc. Biol. - 2006. - Vol. 26. - P. 212-217.
144.Shafey M., Anderson J.L., Scarvelis D. et al. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis // Thromb. Haemost. - 2007. - Vol. 97. - P. 635-641.
Helgadottir              A., Thorleifsson G., Manolescu A. et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction // Science. - 2007. - Vol. 316. - P. 1491-1493.
McPherson              R., Pertsemlidis A., Kavaslar N. et al. A common allele on chromosome 9 associated with coronary heart disease // Science. - 2007. - Vol. 316. - P. 1488-1491.
WTCCC.              Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls // Nature. - 2007. - Vol. 447. - P. 661-678.
Helgadottir              A., Thorleifsson G., Magnusson K.P. et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm // Nat.
Genet. - 2008. - Vol. 40. - P. 217-224.
Thompson              A.R., Golledge J., Cooper J.A. et al. Sequence variant on 9p21 is associated with the presence of abdominal aortic aneurysm disease but does not have an impact on aneurysmal expansion // Eur. J. Hum. Genet. - 2009. - Vol. 17. - P. 391-394.
Talmud              P.J., Cooper J.A., Palmen J. et al. Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men // Clin. Chem. - 2008. - Vol. 54. - P. 467-474.
151.Samani N.J., Erdmann J., Hall A.S., et al. Genomewide association analysis of coronary artery disease // N. Engl. J. Med. - 2007. - Vol. 357. - P. 443-453.
Cowley              A.W., Jr. Long-term control of arterial blood pressure // Physiol. Rev. - 1992. - Vol. 72. - P. 231-300.
Hall              J.E. The kidney, hypertension, and obesity // Hypertension. - 2003. - Vol. 41. - P. 625-633.
Guyton              A.C., Coleman T.G., Granger H.J. Circulation: overall regulation // Annu. Rev. Physiol. - 1972. - Vol. 34. - P. 13-46.
Guyton              A.C. Blood pressure control - special role of the kidneys and body fluids // Science. - Vol. 252. - P. 1813-1816.
Luft              F.C., Miller J.Z., Grim C.E. et al. Salt sensitivity and resistance of blood pressure. Age and race as factors in physiological responses // Hypertension. - 1991. - Vol. 17(Suppl.1): I102-I108.
Hajjar              I.M., Grim C.E., George V. et al. Impact of diet on blood pressure and age-related changes in blood pressure in the US population: analysis of NHANES III // Arch. Intern. Med. - 2001. - Vol. 161. -
P. 589-593.
Lifton              R.P., Dluhy R.G., Powers M. et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension // Nature. - 1992. - Vol. 355. - P. 262-265.
Wilson              F.H., Disse-Nicodeme S., Choate K.A., et al. Human hypertension caused by mutations in WNK kinases // Science. - 2001. - Vol. 293. - P. 1107-1112.
Lifton R.P., Dluhy R.G., Powers M. et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase // Nat. Genet. - 1992. - Vol. 2. - P. 66-74.
161.Shimkets R.A., Warnock D.G., Bositis C.M. et al. Liddle’s syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel // Cell. - 1994. - Vol. 79. - P. 407-414.
Mune              T., Rogerson F.M., Nikkila H. et al. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase // Nat. Genet. - 1995. - Vol. 10. - P. 394-399.
Geller              D.S., Farhi A., Pinkerton N., et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy // Science. - 2000. - Vol. 289. - P. 119-123.
Knight              J., Munroe P.B., Pembroke J.C., et al. Human chromosome 17 in essential hypertension // Ann. Hum. Genet. - 2003. - Vol. 67. - 193-206.
Tikhonoff              V., Kuznetsova T., Stolarz K. et al. beta-Adducin polymorphisms, blood pressure, and sodium excretion in three European populations // Am. J. Hypertens. - 2003. - Vol. 16. - P. 840-846.
Kato              N., Julier C. Linkage mapping for hypertension susceptibility genes // Curr. Hypertens. Rep. - 1999. - Vol. 1. - P. 15-24.